Communique from extra general meeting in Senzime AB (publ)
The extra general meeting in Senzime AB (publ), corp. reg. no 556565-5734 (the “Company”) was held on 5 March 2021 in Uppsala by postal voting in advance whereby the shareholders primarily resolved on the following matters.
Election of new member of the Board of Directors
The extra general meeting resolved to elect Eva Walde as new member of the Board of Directors.
For further information, please contact:
Pia Renaudin, CEO of Senzime AB
Tel: +46 708-13 34 17, e-mail: email@example.com
Uppsala 5 March 2021
Senzime AB (publ)
The board of directors
About SenzimeSenzime develops and markets systems, driven by unique algorithms and sensors, to follow patients' nervous systems and electrical impulses – before, during and after surgery. The company's solution is called TetraGraph, a medical technology system that digitally and continuously measures the degree of neuromuscular blockade in the patient. The goal is improved clinical precision and simplified management in healthcare. By preventing complications and enabling healthcare professionals to follow health care guidelines and drug recommendations, TetraGraph contributes to shorter hospitalizations and lower health care costs – in a world where everyone wakes up safely after surgery. The vision is a world without narcotics-related complications. Senzime operates in growing markets that in Europe and the United States are valued in excess of SEK 10 billion. The company's shares are listed on Nasdaq First North Growth Market (ticker SEZI). FNCA Sweden AB, +46 (0)8-528 00 399, firstname.lastname@example.org, is Certified Adviser for Senzime. www.senzime.com